New MedImmune R&D facility to double its output
This article was originally published in Scrip
While its search for a new permanent CEO continues, MedImmunehas opened a new 92,000sq ft R&D facility at the Granta Park site in Cambridge, UK, as part of an expansion programme that the company hopes will enable it to significantly increase the number of biological drug candidates it can develop each year.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.